Bangkok Genomics Innovation PCLBKK:BKGI -4.55%45 Pretax Margin % is 19.90% as of Dec. 2025, which is 41% above its 10-year median of 14.07. GuruFocus rates BKK:BKGI with a GF Score™ of 45/100. The stock has 12 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 77.83% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's Pretax Margin % or its related term are showing as below:
BKK:BKGI'
s Pretax Margin % Range Over the Past 10 Years
Min: 9.93 Med: 14.07 Max: 27.93
Current: 12.61
BKK:BKGI's Pretax Margin % is ranked better than 77.83% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.56
vs BKK:BKGI: 12.61
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Bangkok Genomics Innovation PCL Pretax Margin % Related Terms
Bangkok Genomics Innovation PCL Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:BKGI vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a Pretax Margin % of 19.90% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 41% above median its historical median of 14.07. Over the past decade, Bangkok Genomics Innovation PCL's Pretax Margin % has ranged from 9.93 to 27.93. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 22.2%.
Is Bangkok Genomics Innovation PCL's Pretax Margin % too high?
Bangkok Genomics Innovation PCL's current Pretax Margin % of 19.90% is 41% above median its 10-year median of 14.07. Over the past 10 years, this metric has ranged from a low of 9.93 to a high of 27.93. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #45 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 45/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #45 out of 203 companies for Pretax Margin %. This places Bangkok Genomics Innovation PCL in the top 22% of its industry — outperforming the majority of peers. Historically, Bangkok Genomics Innovation PCL's own Pretax Margin % has ranged from 9.93 to 27.93 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Bangkok Genomics Innovation PCL and its competitors. Bangkok Genomics Innovation PCL's current Pretax Margin % is 19.90%, which is 41% above median its own 10-year median of 14.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current Pretax Margin % of 19.90%. The current Pretax Margin % is 19.90%, which is 41% above median its 10-year median of 14.07. Bangkok Genomics Innovation PCL's overall GF Score™ is 45/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current Pretax Margin % is 19.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL Business Description
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
45GF Score
Get the complete analysis for BKK:BKGI
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
